EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm

Stéphane De Botton iD, Christian Récher, Jorge Cortes, Antonio Curti iD, Pierre Fenaux iD, Pierre Peterlin iD, Arnaud Pigneux, Karen Yee, Andrew Wei, Alice Mims, Gary Schiller, Mwe Mwe Chao und 2 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.19944 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Stéphane De Botton und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hematologie Clinique, Institut Gustave Roussy, Villejuif, France. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Isocitrate Dehydrogenase, Myeloproliferative Disorders, Mutation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Rigel Pharmaceuticals, Inc., Forma Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukaemia (AML) arising from a myeloproliferative neoplasm (MPN) is more aggressive and less responsive to therapies compared to de novo AML. Olutasidenib, an oral small‐molecule inhibitor of mutated IDH1 (mIDH1), showed encouraging and durable responses in a phase 1/2 study of adults with post‐MPN m IDH1 AML. Patients received olutasidenib 150 mg BID monotherapy or in combination with azacitidine. Primary end‐points: safety and best response defined as complete remission (CR), CR with partial haematological recovery or morphological leukaemia‐free state (MLFS). Analysis included 15 patients with post‐MPN m IDH1 AML; 10 had relapsed or refractory AML and five had newly diagnosed AML. Six were treated with olutasidenib monotherapy and nine in combination with azacitidine. Treatment emergent adverse events occurred in 15 patients, three of whom discontinued therapy. CR: 40% ( n = 6/15); median duration of response: 15.6 months (range: 1.7–44.3); CR with incomplete haematological recovery: 13% ( n = 2/15); MLFS: 7% ( n = 1/15); composite complete remission (CRc): 53% ( n = 8/15); and overall response rate (ORR): 60% (9/18). Median duration of CRc and ORR: 13.15 (range: 2.4–48.7) and 14.3 months (range: 2.4–48.7), respectively, and median overall survival: 13.8 months (95% confidence interval: 3.70–23.7). Olutasidenib demonstrated encouraging response rates with a manageable safety profile for patients with post‐MPN m IDH1 AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteIsocitrate DehydrogenaseMyeloproliferative DisordersMutationPyridinesNeoplasms, Second PrimaryAntineoplastic AgentsHumansMiddle AgedFemaleMaleAgedAdultAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeAzacitidine

Stichwörter der Autor:innen

IDH1 mutationacute myeloid leukaemiablast‐phase myeloproliferative neoplasmmyeloproliferative neoplasms

Substanzen

Isocitrate DehydrogenaseIDH1 protein, humanPyridinesAzacitidineAntineoplastic Agents

Autor:innen und Institutionen

  • Hematologie Clinique, Institut Gustave Roussy, Villejuif, France.
  • Université Paris-Saclay, Villejuif, France.
  • Service d'hématologie, CHU de Toulouse, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France.
  • Georgia Cancer Center, Augusta University, Augusta, Georgia, USA.
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Institute of Hematology Seràgnoli, Bologna, Italy.
  • Département (DMU) d'hematologie et immunologie, APHP Nord, Service d'hématologie séniors, Hôpital St Louis/Université de Paris, Paris, France.

ORCID-Profile: Stéphane De Botton, Antonio Curti, Pierre Fenaux, Pierre Peterlin

Förderung

  • Rigel Pharmaceuticals, Inc.
  • Forma Therapeutics

Zitieren

APA

De Botton, S., Récher, C., Cortes, J., Curti, A., Fenaux, P., Peterlin, P., Pigneux, A., Yee, K., Wei, A., Mims, A., Schiller, G., Chao, M. M., Tian, H., & Watts, J. M. (2025). Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm. British Journal of Haematology. https://doi.org/10.1111/bjh.19944

Vancouver

De Botton S, Récher C, Cortes J, Curti A, Fenaux P, Peterlin P, et al. Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm. British Journal of Haematology. 2025. doi:10.1111/bjh.19944

BibTeX
@article{DeBotton2025,
  author = {De Botton, Stéphane and Récher, Christian and Cortes, Jorge and Curti, Antonio and Fenaux, Pierre and Peterlin, Pierre and Pigneux, Arnaud and Yee, Karen and Wei, Andrew and Mims, Alice and Schiller, Gary and Chao, Mwe Mwe and Tian, Hua and Watts, Justin M},
  title = {Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.19944}
}
Kostenlos starten →